{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T08:48:22Z","timestamp":1759826902334},"reference-count":13,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T00:00:00Z","timestamp":1393891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>Safety and efficacy of long\u2010term olanzapine treatment in Japanese patients with bipolar depression were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An integrated analysis of data from two studies was performed in olanzapine\u2010treated patients (<jats:italic>n<\/jats:italic>\u2009=\u2009165) with bipolar depression. Study 1 was a 6\u2010week, double\u2010blind, global study. Patients were randomly assigned to olanzapine or placebo followed by 18 weeks of open\u2010label treatment. Study 2 was an open\u2010label extension of Study 1 involving only Japanese patients. Patients assigned to Pre\u2010olanzapine and Pre\u2010placebo in Study 1 were treated for 24 weeks (total olanzapine exposure 42 or 48 weeks) and newly recruited patients (New\u2010olanzapine) were treated for 48 weeks. Safety outcomes included treatment\u2010emergent adverse events and changes in metabolic parameters. Efficacy outcome was assessed with Montgomery\u2013\u00c5sberg Depression Rating Scale score.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty\u2010three percent of patients completed the 42\u2010 or 48\u2010week olanzapine treatment period. The most common treatment\u2010emergent adverse event was weight increased (47.9%). Significant increases were seen in weight (3.5\u2009kg), and in fasting glucose (3.5\u2009mg\/dL), fasting total cholesterol (8.1\u2009mg\/dL), and fasting triglycerides (35.1\u2009mg\/dL). Remission rates (Montgomery\u2013\u00c5sberg Depression Rating Scale total score \u226412 at any time) were 79.8% for the Pre\u2010olanzapine group, 90.2% for the Pre\u2010placebo group, and 85.0% for the New\u2010olanzapine group. No patents developed mania during treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Long\u2010term use of olanzapine in a Japanese population with bipolar depression is associated with increases in weight and fasting metabolic measures, and also with improved depressive symptoms with avoidance of mania. Clinicians must carefully consider the benefits and risks of long\u2010term therapy with olanzapine.<\/jats:p><\/jats:sec>","DOI":"10.1111\/pcn.12156","type":"journal-article","created":{"date-parts":[[2014,1,13]],"date-time":"2014-01-13T07:24:40Z","timestamp":1389597880000},"page":"498-505","source":"Crossref","is-referenced-by-count":7,"title":["Safety and efficacy of olanzapine in the long\u2010term treatment of <scp>J<\/scp>apanese patients with bipolar <scp>I<\/scp> disorder, depression: An integrated analysis"],"prefix":"10.1111","volume":"68","author":[{"given":"Hideaki","family":"Katagiri","sequence":"first","affiliation":[{"name":"Eli Lilly Japan K.K.  Kobe Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricio","family":"Tohen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of New Mexico School of Medicine  Albuquerque USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"McDonnell","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories Eli Lilly and Company  Indianapolis USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Fujikoshi","sequence":"additional","affiliation":[{"name":"Eli Lilly Japan K.K.  Kobe Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Case","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories Eli Lilly and Company  Indianapolis USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigenobu","family":"Kanba","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Graduate School of Medical Sciences Kyushu University  Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Eli Lilly Japan K.K.  Kobe Japan"},{"name":"Takahashi Psychiatric Clinic  Ashiya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan\u2010Carlos","family":"Gomez","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories Eli Lilly and Company  Indianapolis USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,3,4]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.112.108357"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-138"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2486"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-S067"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00726.x"},{"key":"e_1_2_6_10_1","unstructured":"Zyprexa [package insert]. Eli Lilly and Company Indianapolis IN 2011."},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110370505"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2010.0020"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.12.2099"}],"container-title":["Psychiatry and Clinical Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpcn.12156","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pcn.12156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T08:29:24Z","timestamp":1696148964000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pcn.12156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,4]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1111\/pcn.12156"],"URL":"https:\/\/doi.org\/10.1111\/pcn.12156","archive":["Portico"],"relation":{},"ISSN":["1323-1316","1440-1819"],"issn-type":[{"value":"1323-1316","type":"print"},{"value":"1440-1819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,4]]}}}